RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 190 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $521,057 | +6.2% | 68,112 | +3.7% | 0.00% | 0.0% |
Q2 2023 | $490,704 | +11.5% | 65,690 | -0.4% | 0.00% | 0.0% |
Q1 2023 | $439,927 | -11.7% | 65,956 | +2.0% | 0.00% | 0.0% |
Q4 2022 | $498,413 | -27.8% | 64,645 | -0.4% | 0.00% | -40.0% |
Q3 2022 | $690,000 | +34.0% | 64,880 | +2.5% | 0.01% | +66.7% |
Q2 2022 | $515,000 | +25.6% | 63,291 | +10.6% | 0.00% | +50.0% |
Q1 2022 | $410,000 | -60.9% | 57,225 | -6.6% | 0.00% | -60.0% |
Q4 2021 | $1,049,000 | +196.3% | 61,251 | +297.7% | 0.01% | +150.0% |
Q3 2021 | $354,000 | -18.1% | 15,400 | +30.1% | 0.00% | +100.0% |
Q2 2021 | $432,000 | – | 11,839 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Obvious Management Services, L.L.C. | 3,985,087 | $42,401,000 | 100.00% |
Two Sigma Ventures, LP | 903,400 | $9,612,000 | 100.00% |
DCVC Opportunity Fund II GP, LLC | 3,951,141 | $42,040,000 | 54.37% |
Data Collective IV GP, LLC | 5,941,120 | $63,214,000 | 49.97% |
MIC Capital Management UK LLP | 8,451,758 | $89,927,000 | 16.21% |
MV Management XI, L.L.C. | 1,971,908 | $20,981,000 | 15.20% |
ArchPoint Investors | 1,116,126 | $11,876,000 | 4.85% |
HARVARD MANAGEMENT CO INC | 1,509,254 | $16,058,000 | 2.00% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,251,971 | $23,961,000 | 1.00% |
Duquesne Family Office | 1,385,950 | $14,747,000 | 0.84% |